Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Antineoplastic Agents, Immunological
/ pharmacology
B7-H1 Antigen
/ antagonists & inhibitors
Biomarkers, Tumor
/ genetics
DNA Mutational Analysis
Drug Resistance, Neoplasm
/ genetics
Genetic Testing
/ methods
Humans
Immunotherapy
/ methods
Mutation
Neoplasms
/ drug therapy
Patient Selection
Programmed Cell Death 1 Receptor
/ agonists
Biomarker
Immunotherapy
Tumour mutational burden
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
12
2019
accepted:
13
02
2020
pubmed:
13
4
2020
medline:
28
10
2020
entrez:
13
4
2020
Statut:
ppublish
Résumé
Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an emerging biomarker for response to PD-1/PD-L1 inhibitors. The evaluation of this biomarker is based on the hypothesis that a high number of mutations in somatic exonic regions will lead to an increase in neoantigen production, which could then be recognised by CD8
Identifiants
pubmed: 32278982
pii: S0959-8049(20)30112-X
doi: 10.1016/j.ejca.2020.02.038
pmc: PMC9473693
mid: NIHMS1835439
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-50Subventions
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Mol Diagn Ther. 2019 Aug;23(4):507-520
pubmed: 31250328
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Thorac Oncol. 2017 Feb;12(2):258-268
pubmed: 27865871
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
J Thorac Oncol. 2019 Jan;14(1):124-129
pubmed: 30138764
Clin Cancer Res. 2019 Feb 1;25(3):957-966
pubmed: 30154227
Nat Med. 2019 Nov;25(11):1706-1714
pubmed: 31686036
Nucleic Acids Res. 2017 Jan 4;45(D1):D840-D845
pubmed: 27899611
Front Oncol. 2019 Nov 05;9:1161
pubmed: 31750249
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Int J Cancer. 2019 Feb 15;144(4):848-858
pubmed: 30238975
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
PLoS Med. 2017 May 26;14(5):e1002309
pubmed: 28552987
Cancers (Basel). 2019 Nov 04;11(11):
pubmed: 31690036
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
J Immunother Cancer. 2019 Jul 12;7(1):180
pubmed: 31300034
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Mol Oncol. 2015 May;9(5):960-6
pubmed: 25458054
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Br J Cancer. 2018 Oct;119(8):950-960
pubmed: 30318514
Lancet Oncol. 2016 Jul;17(7):943-955
pubmed: 27269740
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Clin Cancer Res. 2019 Dec 15;25(24):7413-7423
pubmed: 31515453
JAMA Oncol. 2019 Aug 01;5(8):1195-1204
pubmed: 31318407
Ann Oncol. 2019 Sep 1;30(9):1496-1506
pubmed: 31268125
Sci Transl Med. 2019 Aug 21;11(506):
pubmed: 31434757
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
J Pathol Transl Med. 2019 Jul;53(4):199-206
pubmed: 31042863
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585